Must-read for patients: Overview of basic information in the instructions for venetoclax/venetoclax tablets

1. Common names: Venetoclax, Venetoclax

Product name: Venclexta, Venclyxto, Venclyxto

Other names: Venetoclax, Venetoclax, Venetoclax, Venetoclax

2. Who can take Venekra? Indications?

1. Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Venaclat is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

2. Acute myeloid leukemia (AML):Veneclatcan be used in combination with other drugs to treat patients newly diagnosed in adults aged 75 or above Acute myeloid leukemia, or patients with comorbidities that preclude the use of intensive induction chemotherapy, such as azacitidine, decitabine, or low-dose cytarabine.

3. What are the side effects of Venekra?

In patients with CLL/SLL, the most common side effects (≥20%) were neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema. In patients with AML, the most common side effects (≥30%) were nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, bleeding, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, and cough.

4. How should I take Venekra?

1. Before use: Assess patient-specific factors for tumor lysis syndrome (TLS) risk level, and provide patients with prophylactic hydration and anti-hyperuricemia before taking venetoclax for the first time to reduce the risk of TLS.

2. Usage and dosage:

(1) For patients with CLL/SLL, the starting dose of venetoclax is 20mg daily and gradually increase to 40mg daily over five weeks 0 mg (20 mg for the first week, 50 mg for the second week, 100 mg for the third week, and 200 mg daily for the fourth week), then continue at a daily dose of 400 mg, with the duration of treatment depending on which drug is taken with it. When used aloneVeneclase should be used as long as treatment continues to be effective.

(2) For patients with AML, the starting dose is 100mg, increasing to 400mg daily over three days (Article The dose is 100 mg on the first day, 200 mg on the second day, and 400 mg on the third day). If certain side effects occur, the dose may need to be reduced or the treatment may be interrupted or stopped. Coadministration should follow its prescribing information.

3. Medication management: When taking Venetoclax, you need to have food and water. Take it at about the same time every day, and swallow the Venetacla tablets whole. Do not chew, crush, or break tablets before swallowing. The recommended dosage of venetoclax can be delivered using any approved tablet strength (e.g. patients may take 2*50mg tablets or 10*10mg tablets as needed, rather than 1*100mg tablet).

If a patient misses a dose within 8 hours of their usual dose of venetoclax, instruct the patient to take the missed dose as soon as possible and resume their normal daily dosing schedule. If the patient misses a dose by more than 8 hours, instruct the patient not to take the missed dose and to resume their normal dosing schedule the next day. If the patient vomits after administration, instruct the patient not to take additional doses that day and to take the next prescribed dose at the normal time.

5. How to store Venekra?

Stored in original container86°F (30°C) or below. Dispense medications to patients in their original containers to protect them from moisture.

6. How does Vinacla work?

Venetoclaxis a selective orally bioavailable small molecule inhibitor of the anti-apoptotic protein BCL-2. Overexpression of BCL-2 has been demonstrated in CLL and AML cells, where it mediates tumor cell survival and is associated with resistance to chemotherapeutic drugs. Venetoclaxhelps restore the apoptosis process by directly binding to BCL-2 protein, replacing pro-apoptotic proteins such as BIM, triggering mitochondrial outer membrane permeabilization and caspase activation. In non-clinical studies, venetoclax has shown cytotoxic activity in tumor cells overexpressing BCL-2.

7. What will happen if you overdose?

There is no specific antidote for venetoclax. For patients with overdose, monitor closely and provide appropriate supportive care; interrupt venetoclax during the ramp-up phase and carefully monitor for signs and symptoms of TLS and other toxicities. Based onthe substantial distribution and extensive protein binding of venetoclax, it is unlikely that dialysis results in significant clearance of venetoclax. In case of overdose, your doctor should be notified immediately and intervention should be initiated.